Vesalius Longevity Labs is building the leading global peptide and longevity brand: physician-led, science-grounded, and backed by traceable U.S. manufacturing.
Vesalius Longevity Labs is a peptide and longevity company that brings emerging science to patients through the people they trust most: their licensed healthcare providers. We combine clinical rigor, regulatory discipline and a growing global network to help people pursue healthier aging.
Today we work with over 350 providers worldwide, with expansion underway in Latin America and beyond.
Many adults experience metabolic and hormonal changes as they age, and interest in approaches that may support healthy aging has never been higher. Peptides are short chains of amino acids that act as signalling molecules in the body and are one of the most active areas of research in preventive and proactive healthcare, with studies spanning cognition, recovery, immune and metabolic function, and hormone and aging-related pathways.
Vesalius connects that science to clinical practice. We support the licensed providers who prescribe peptide therapies and invest in the manufacturing and distribution infrastructure that keeps quality, traceability and availability within their reach.
Our flagship line of peptide formulations, available through licensed providers on our proprietary platform. Peptual® products come in multiple delivery formats, including lyophilized (freeze-dried) preparations, injectable pens for measured-dose delivery, nasal sprays and transdermal patches.
Pre-measured injectable pens designed for convenience and consistency, available through distribution partners and multi-location clinic operators outside the United States, including our upcoming UAE launch.
A direct pathway for patients to connect with licensed providers online, receive an evaluation, and, where appropriate, obtain a prescription fulfilled through participating pharmacies.
Through an exclusive agreement with Celularity (NASDAQ: CELU), Vesalius has established a first-of-its-kind U.S. final-stage manufacturing and supply platform for Peptual® active pharmaceutical ingredients, finished in Florham Park, New Jersey, with lot-level traceability from bulk material to final release.
Through our subsidiary Royal Longevity (RegenProcessing.com), Vesalius distributes Dezawa MuseCells® products made by a U.S. lab licensed by MuseCell Innovations. Muse cells were first reported in 2010 by Professor Mari Dezawa’s group at Tohoku University and are the subject of more than 170 global publications. The line also includes Dezawa MuseExosomes® in collaboration with Peptual Skin.
Our CEO is a practicing physician-executive with more than 20 years in regenerative medicine and regulated healthcare. Our scientific advisory board includes specialists in longevity, regenerative orthopedics, sports medicine, obesity medicine and pain management, from institutions including Harvard, Stanford, Dartmouth, Yale, Cedars-Sinai and the Hospital for Special Surgery.
Our model puts licensed clinicians at the centre of every patient relationship. Every Vesalius product is prescription-only, so care decisions stay where they belong.
Our exclusive partnership with Celularity gives us something few in the peptide space can offer: U.S.-based final-stage API finishing, peptide-specific processes built to cGMP requirements, and lot-level traceability from source to release.
We operate across the full value chain (API supply, pharmacy, product, delivery devices, telemedicine and clinic distribution), giving providers one trusted partner instead of many.
Through our Dezawa MuseCells® distribution, Vesalius offers providers access to both peptide therapies and next-generation regenerative products.
Active in the U.S., EU and UAE, with Mexico pending regulatory approval and planned expansion into South America, Australia, Japan and the Middle East.
Our strategic advisors, leaders across health, performance and culture, bring a combined social following of roughly 50 million, helping build trust and awareness for the longevity category.
Information on this site is for general informational purposes only and is not medical advice. Vesalius products are compounded medications available only by prescription from a licensed healthcare provider. Compounded drugs are not approved by the U.S. Food and Drug Administration, and statements about their potential benefits have not been evaluated by the FDA. Dezawa MuseCells® products have not been evaluated or approved by the FDA and are not intended to diagnose, treat, cure or prevent any disease. Their availability in the U.S. is limited to states that permit such therapies, and any clinical use is at the sole discretion of a licensed healthcare provider. Individual results may vary.
Licensed healthcare providers can request provider information to start the review for a Vesalius account.
Disclaimer: The information provided on this website is intended for general educational and informational purposes only. Vesalius Longevity Labs provides information relating to peptide science, longevity, wellness, metabolic health, and emerging areas of medical research.
FDA Approval & Investigational Therapies: Not all peptides, compounds, medications, or therapies discussed or referenced on this website are approved by the U.S. Food and Drug Administration (FDA). Certain compounds may be investigational, have limited clinical evidence, or lack established long-term safety and efficacy data. References to scientific research, emerging therapies, or potential health benefits are provided for informational purposes and should not be interpreted as claims of FDA approval, established clinical effectiveness, or guaranteed therapeutic outcomes. Where legally permitted, certain medications may be compounded by appropriately licensed pharmacies in accordance with applicable federal and state laws. Compounded medications are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before marketing in the same manner as FDA-approved medications. Read the full disclaimer.
